BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 2016615)

  • 1. Improved survival in patients with poor-prognosis malignant melanoma treated with adjuvant levamisole: a phase III study by the National Cancer Institute of Canada Clinical Trials Group.
    Quirt IC; Shelley WE; Pater JL; Bodurtha AJ; McCulloch PB; McPherson TA; Paterson AH; Prentice R; Silver HK; Willan AR
    J Clin Oncol; 1991 May; 9(5):729-35. PubMed ID: 2016615
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of adjuvant therapy in melanoma management.
    Barth A; Morton DL
    Cancer; 1995 Jan; 75(2 Suppl):726-34. PubMed ID: 7805001
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjuvant BCG immunotherapy for stage I and II malignant melanoma.
    Silver HK; Ibrahim EM; Evers JA; Thomas JW; Murray RN; Spinelli JJ
    Can Med Assoc J; 1983 Jun; 128(11):1291-5. PubMed ID: 6342739
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized trial of levamisole versus placebo as adjuvant therapy in malignant melanoma.
    Spitler LE
    J Clin Oncol; 1991 May; 9(5):736-40. PubMed ID: 2016616
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic value of tuberculin and BCG immunoreactivity in stage I high-risk malignant melanoma (EORTC protocol 18781).
    Henz BM; Macher E; Bröcker EB; Suciu S; Steerenberg PA; Jung E; Rümke P
    Dermatology; 1996; 193(2):105-9. PubMed ID: 8884144
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Corynebacterium parvum versus bacille Calmette-Guérin adjuvant immunotherapy of stage II malignant melanoma.
    Lipton A; Harvey HA; Balch CM; Antle CE; Heckard R; Bartolucci AA
    J Clin Oncol; 1991 Jul; 9(7):1151-6. PubMed ID: 2045856
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside.
    Livingston PO; Wong GY; Adluri S; Tao Y; Padavan M; Parente R; Hanlon C; Calves MJ; Helling F; Ritter G
    J Clin Oncol; 1994 May; 12(5):1036-44. PubMed ID: 8164027
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preliminary results of combined surgery and adjuvant Bacillus Calmette-Guérin plus levamisole treatment of resectable lung cancer.
    Wright PW; Hill LD; Peterson AV; Pinkham R; Johnson L; Ivey T; Bernstein I; Bagley C; Anderson R
    Cancer Treat Rep; 1978 Nov; 62(11):1671-5. PubMed ID: 215304
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvant therapy of melanoma.
    Agarwala SS; Kirkwood JM
    Semin Surg Oncol; 1998 Jun; 14(4):302-10. PubMed ID: 9588723
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Results of adjuvant BCG immunotherapy in malignant melanoma.
    Wätzig V; Knopf B
    Arch Geschwulstforsch; 1981; 51(6):493-6. PubMed ID: 7332442
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recurrent malignant melanoma: effect of adjuvant immunotherapy on survival.
    McCulloch PB; Dent PB; Blajchman M; Muirhead WM; Price RA
    Can Med Assoc J; 1977 Jul; 117(1):33-6. PubMed ID: 861909
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized controlled trial of adjuvant chemoimmunotherapy with DTIC and BCG after complete excision of primary melanoma with a poor prognosis or melanoma metastases.
    Can Med Assoc J; 1983 Apr; 128(8):929-33. PubMed ID: 6339024
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjuvant combination immunotherapy (BCG and levamisole) in malignant melanoma.
    Dandapat MC; Mohapatra SK; Patra SK
    Indian J Cancer; 1985 Jun; 22(2):100-7. PubMed ID: 3842124
    [No Abstract]   [Full Text] [Related]  

  • 14. Adjuvant reactivity predicts survival in patients with "high-risk" primary malignant melanoma treated with systemic BCG. EORTC Malignant Melanoma Cooperative Group Writing Committee.
    Cochran AJ; Buyse ME; Lejeune FJ; Macher E; Revuz J; Rümke P
    Int J Cancer; 1981 Nov; 28(5):543-50. PubMed ID: 7309294
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjuvant treatment in stage I and II malignant melanoma: a randomized trial between chemoimmunotherapy and immunotherapy.
    Castel T; Estapé J; Viñolas N; Mascaró JM; Castro J; Vilalta A; Gratacós R; Daniels M; Palou J; Grau JJ
    Dermatologica; 1991; 183(1):25-30. PubMed ID: 1769411
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mature results of a phase III randomized trial of bacillus Calmette-Guerin (BCG) versus observation and BCG plus dacarbazine versus BCG in the adjuvant therapy of American Joint Committee on Cancer Stage I-III melanoma (E1673): a trial of the Eastern Oncology Group.
    Agarwala SS; Neuberg D; Park Y; Kirkwood JM
    Cancer; 2004 Apr; 100(8):1692-8. PubMed ID: 15073858
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of levamisole as a surgical adjuvant therapy for malignant melanoma.
    Gonzalez RL; Spitler LE; Sagebiel RW
    Cancer Treat Rep; 1978 Nov; 62(11):1703-7. PubMed ID: 365324
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of age on the efficacy of maintenance bacillus Calmette-Guérin relative to maintenance epirubicin in patients with stage Ta T1 urothelial bladder cancer: results from EORTC genito-urinary group study 30911.
    Oddens JR; Sylvester RJ; Brausi MA; Kirkels WJ; van de Beek C; van Andel G; de Reijke TM; Prescott S; Witjes JA; Oosterlinck W
    Eur Urol; 2014 Oct; 66(4):694-701. PubMed ID: 24948466
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preliminary results of a randomized trial of adjuvant immunotherapy in patients with malignant melanoma who have lymph node metastases.
    Morton DL; Eilber FR; Holmes EC; Ramming KP
    Aust N Z J Surg; 1978 Feb; 48(1):49-52. PubMed ID: 276348
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized trial of levamisole versus placebo as adjuvant therapy in malignant melanoma.
    Spitler LE; Sagebiel R
    N Engl J Med; 1980 Nov; 303(20):1143-7. PubMed ID: 6999349
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.